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Introduction
Nevirapine (viramune) is a nonnucleoside reverse
transcriptase inhibitor commonly used in combination
with other antiretroviral medicines in the treatment of
HIV/AIDS. The safety profile of nevirapine, as
determined by review of prospective clinical trials1,
reports rash with an incidence of 16% as the most
common side effect. Clinical hepatitis is reported to
occur with an incidence of 1%. A review of the literature
shows many case reports of nevirapine-induced hepato-
toxicity in patients receiving both treatment and
prophylaxis for HIV2-6. The purpose of this case report is
to stress the importance of early recognition and
withdrawal of the offending drug.
Case Report
A 48 year old African American male with a past medical
history of AIDS, chronic hepatitis C, and hypertension
presented as a transfer from an outside hospital with a rash
and elevated aminotransferases. Since diagnosis of AIDS
in 1995, the patient had been on lamivudine, zidovudine,
and indinavir with an undetectable viral load and CD4
count of 253 cells/ul. Due to recurrent kidney stones, the
patient was switched from indinavir to nevirapine about
three weeks prior to admission. Nevirapine was started at
low dose for two weeks before increasing to full dose
therapy. After three days of full dose therapy, he noted
fever, chills, and diffuse body aches.
The patient reported to the emergency room and was
admitted with a fever of 101 F. At the time of admission,
he denied headache, sore throat, stiff neck, shortness of
breath, cough, abdominal pain, arthralgia, or rash.
Physical exam revealed sinus tenderness, anicteric sclera,
no pharyngeal erythema or exudate, supple neck, clear
lungs, regular heart rate and rhythm, soft non-tender
abdomen with no hepatomegaly, non-focal neurologic
exam, and no rash. Complete blood count and
chemistries were within normal limits. Liver chemistries
were not ordered at initial presentation. Chest x-ray
showed new mild elevation of right hemi-diaphragm
with no consolidation. Sinus x-rays was normal.
The patient was started on ampicillin/sulbactam after
which he developed a diffuse erythematous rash that
resolved with discontinuation of antibiotics and adminis-
tration of intravenous methylprednisolone and diphen-
hydramine. The fever did not recur with discontinuation
of antibiotics. He was discharged on his admission
antiretroviral medications. A few days after discharge,
the fever and rash reappeared along with scleral icteris
and light colored loose stool. He was readmitted and
then transferred to our hospital.
On admission, he denied any alcohol since 1995, denied
any recent travel or ingestion of contaminated food,
denied taking any over the counter drugs, vitamins, or
herbal remedies. He also denied any family history of
liver disease. He admitted to having been vaccinated
against hepatitis A and B. He was taking
lamivudine/zidovudine, clonidine, atenolol, fosinopril,
and furosemide. He chose to stop taking the nevirapine,
believing that it might have been responsible for his
illness. Physical exam was notable for scleral icterus,
hepatomegaly, and diffuse erythematous maculopapular
rash. Total bilirubin was 6.6 mg/dl, direct bilirubin 4.1
mg/dl, ALT 173 U/L, and INR 1.2. Abdominal
ultrasound showed only hepatomegaly.
The patient was believed to have nevirapine-induced
hepatitis. All medicines were held. ALT peaked at 720 U/L
(hospital day seven). Total bilirubin peaked at 30.9 mg/dl
(hospital day nine). INR peaked at 2.0 (hospital day nine).
The rash improved steadily, hepatomegaly resolved, and
the patient remained afebrile. Blood and urine cultures
were negative. Hepatitis A virus IgM, Hepatitis B virus
core IgM, Hepatitis B virus surface antigen, and
acetaminophen levels were all negative. The patient was
discharged on hospital day eleven. His liver function tests
returned to baseline over the next five months.
Discussion
Hepatotoxicity is a potential complication of many
common drugs. As new drugs enter clinical practice, case
reports of drug-induced hepatotoxicity will follow. Such
is the case with nevirapine. Since its introduction in
1996, several case reports have described severe toxic
hepatitis. Drug induced hepatotoxicity is a relatively
uncommon cause of acute hepatitis, but it is an
important one. Risk factors for hepatotoxicity include
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age, gender, history of adverse drug reaction,
polypharmacy, alcohol use, poor nutritional status, pre-
existing liver disease, and certain systemic diseases. Drug-
induced liver disease can mimic the clinicopathologic
presentation of nearly all known liver diseases.
Clinicopathologic features can therefore organize the
classification of hepatotoxicity. Presentation can include
acute or chronic hepatitis, acute or chronic cholestasis,
mixed cholestatic hepatitis, fibrosis/cirrhosis, vascular
injury, and tumors. Hepatotoxicity can be dose
dependent or idiosyncratic. The clinical presentation of
hepatotoxicity often includes early prodromal symptoms
which if recognized, can allow early diagnosis and
withdrawal of the toxic agent. These symptoms include
fever, rash, mucositis, eosinophilia, lymphadenopathy, a
mononucleosis-type syndrome, bone marrow
suppression, vasculitis, renal failure, pneumonitis, and
pancreatitis. Early diagnosis ultimately depends on high
clinical suspicion. The physician must recognize these
subtle symptoms and ask detailed questions concerning
recent and remote drug history. Drug history must
include temporal relationship to symptoms, doses, and
use of non-prescription or herbal drugs. Diagnosis of
drug-induced liver injury, however, can only be made
after exclusion of infectious, autoimmune, vascular, and
metabolic etiologies. There is no treatment other than
removal of the offending agent and supportive care. This
makes early detection the most significant task for the
physician.
In this case, the patient presented with fever, malaise,
myalgias, recent change in medication, and history of
chronic hepatitis C. On initial presentation, no liver
function studies were checked. In the previously reported
cases of nevirapine hepatotoxicity2-6, symptoms occurred
from two to six weeks after starting the drug. Nonspecific
symptoms were uniformly present and included fever,
rash, arthralgia, and malaise. Patterns of liver chemistries
included pure hepatocellular, pure cholestasis, and mixed
cholestatic hepatitis. In addition to recognition of early
symptoms, recognition of risk factors can aid in early
diagnosis by raising clinical suspicion. Two studies have
looked at chronic hepatitis B or C as risk factors for
hepatotoxicity during HAART in HIV patients. Both
studies concluded that hepatotoxicity to HAART is more
likely in patients co-infected with hepatitis B or C9,10.
This case serves as a reminder that hepatotoxicity is still
overlooked during it’s early phase. 
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